Paola Cavalcante

List of Publications by Year
in descending order

42 papers	1,647 citations	279798 23 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	2310 citing authors

#	Article	IF	Citations
1	A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics, 2005, 85, 258-263.	2.9	339
2	Epsteinâ€Barr virus persistence and reactivation in myasthenia gravis thymus. Annals of Neurology, 2010, 67, 726-738.	5.3	103
3	Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. Experimental Neurology, 2011, 231, 30-37.	4.1	81
4	Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics, 2007, 89, 143-150.	2.9	78
5	Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmunity Reviews, 2013, 12, 863-874.	5.8	75
6	Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. Journal of Neuroimmunology, 2008, 201-202, 237-244.	2.3	73
7	Autoimmune mechanisms in myasthenia gravis. Current Opinion in Neurology, 2012, 25, 621-629.	3.6	62
8	Innate immunity in myasthenia gravis thymus: Pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. Journal of Autoimmunity, 2014, 52, 74-89.	6.5	62
9	Myasthenia gravis: from autoantibodies to therapy. Current Opinion in Neurology, 2018, 31, 517-525.	3.6	58
10	The thymus in myasthenia gravis: Site of â€œinnate autoimmunityâ€?. Muscle and Nerve, 2011, 44, 467-484.	2.2	56
11	Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology, 2010, 74, 1118-1126.	1.1	51
12	Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage. Molecular Brain, 2015, 8, 5.	2.6	49
13	Gene expression of cytokines and cytokine receptors is modulated by the common variability of the mitochondrial DNA in cybrid cell lines. Genes To Cells, 2006, 11, 883-891.	1.2	47
14	Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epsteinâ€“Barr virus infection. Immunobiology, 2016, 221, 516-527.	1.9	47
15	Diagnosis and treatment of myasthenia gravis. Current Opinion in Rheumatology, 2019, 31, 623-633.	4.3	40
16	A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology, 2016, 221, 1227-1236.	1.9	33
17	Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. Experimental Neurology, 2014, 253, 91-101.	4.1	31
18	Tollâ€like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?. Annals of the New York Academy of Sciences, 2018, 1413, 11-24.	3.8	28

#	Article	IF	Citations
19	<scp>VAV</scp>1 and <scp>BAFF</scp>, via <scp>NF</scp>ÎºB pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 2014, 1, 329-339.	3.7	27
20	Complement Inhibition for the Treatment of Myasthenia Gravis . ImmunoTargets and Therapy, 2020, Volume 9, 317-331.	5.8	27
21	FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice. Cells, 2019, 8, 279.	4.1	26
22	miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids. Frontiers in Immunology, 2020, 11, 142.	4.8	26
23	Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis. Autoimmune Diseases, 2011, 2011, 1-17.	0.6	25
24	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget, 2015, 6, 7424-7437.	1.8	25
25	Elevated TGF Î²2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. Nucleus, 2018, 9, 337-349.	2.2	25
26	Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?. Oncotarget, 2017, 8, 95432-95449.	1.8	23
27	A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. Journal of Clinical Pharmacology, 2013, 53, 67-74.	2.0	21
28	MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. Pharmacological Research, 2019, 148, 104388.	7.1	16
29	BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology. Journal of Neuroimmunology, 2008, 197, 128-139.	2.3	14
30	Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. Neuroscience, 2019, 416, 88-99.	2.3	14
31	Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. International Journal of Molecular Sciences, 2021, 22, 5673.	4.1	14
32	Postinfectious Neurologic Complications in COVID-19: AÂComplex Case Report. Journal of Nuclear Medicine, 2021, 62, 1171-1176.	5.0	12
33	Eculizumab for the treatment of myasthenia gravis. Expert Opinion on Biological Therapy, 2020, 20, 991-998.	3.1	10
34	Epsteinâ€barr virus in myasthenia gravis thymus: A matter of debate. Annals of Neurology, 2011, 70, 519-519.	5.3	9
35	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. Cells, 2020, 9, 1532.	4.1	8
36	COVIDâ€19â€associated immuneâ€mediated encephalitis mimicking acuteâ€onset Creutzfeldtâ€Jakob disease. Annals of Clinical and Translational Neurology, 2021, 8, 2314.	3.7	5

#	Article	IF	Citations
37	Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations. Frontiers in Immunology, 2021, 12, 667336.	4.8	3
38	Pharmacogenetic and pharmaco-miR biomarkers for tailoring and monitoring myasthenia gravis treatments. Expert Review of Precision Medicine and Drug Development, 2020, 5, 317-329.	0.7	2
39	Paraneoplastic autoimmune diseases in patients with thymic malignancies: a favorable, but not independent, prognostic factor. Mediastinum, 0, 2, 41-41.	1.1	1
40	Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy. Biomedicines, 2022, 10, 1360.	3.2	1
41	Revealing the involvement of miR-376a, miR-432 and miR-451a in infantile ascending hereditary spastic paralysis by microRNA profiling in iPSCs. Journal of Translational Science, 2018, 5, .	0.2	0
42	Epstein-Barr Virus in Myasthenia Gravis: Key Contributing Factor Linking Innate Immunity with B-Cell-Mediated Autoimmunity. , 0, , .		0